Latest Conference Coverage

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center discussed opportunities for MR fingerprinting to expand, both in the epilepsy field and in general neurology. [WATCH TIME 3 minutes]

The clinical psychologist at Cleveland Clinic provided insight on the tricky nature of diagnosing a patient with nonepileptic seizures and the difficult conversations that can ensue. [WATCH TIME: 3 minutes]

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided insight on her study presented at AES 2021, which showed that MR fingerprinting can differentiate focal cortical dysplasia from healthy tissue. [WATCH TIME: 4 minutes]

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center discussed why MR fingerprinting holds significant clinical potential in epilepsy and epilepsy-related disorders.

Darcy Krueger, MD, PhD, director, Tuberous Sclerosis Clinic, Cincinnati Children’s, discussed the idea behind swiftly treating tuberous sclerosis at infant stages using targeted therapeutic approaches.

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided background on the momentum behind MR fingerprinting and its potential in epilepsy care. [WATCH TIME: 3 minutes]

The clinical psychologist at Cleveland Clinic discussed the process for successfully changing and tailoring different cognitive behavioral therapy approaches to treat various forms of seizures. [WATCH TIME: 3 minutes]

The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s discussed the thought behind STOPS2, a trial aimed at preventing or delaying seizure onset in tuberous sclerosis complex. [WATCH TIME: 3 minutes]

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, provided context on improving our use of current antiseizure medications as the top priority for patients with epilepsy. [WATCH TIME: 2 minutes]

The staff neurologist at the Cleveland Clinic Mellen Center for Multiple Sclerosis outlined key findings from her talk at a recent Institutional Perspectives in Neurology: Multiple Sclerosis event. [WATCH TIME: 3 minutes]

The director of the epilepsy center at Cleveland Clinic Neurological Institute spoke on one of the studies he coauthored that were presented at AES 2021. [WATCH TIME: 4 minutes]

The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s provided insight on promising drug developments for tuberous sclerosis complex and other notable priorities within the space.

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed the need for specificity and artificial intelligence for patients with epilepsy. [WATCH TIME: 4 minutes]

Jessica Fesler, MD, MEd, staff epileptologist, Cleveland Clinic, offered insight on the future of seizure apps and how if improved, they could alter the treatment of patients with epilepsy.

The medical director of the Epilepsy program at the University of Toronto discussed her presentation at AES 2021 regarding the need to change how clinicians view and treat patients with developmental epileptic encephalopathies.

Neurology News Network for the week ending December 11, 2021. [WATCH TIME: 4 minutes]

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute spoke on the latest advances with epilepsy surgery, as well as what still needs to be learned. [WATCH TIME: 5 minutes]

Leaders in the epilepsy space provided their thoughts on the most promising aspects, initial takeaways, and dominating conversations at the 2021 American Epilepsy Society annual meeting.

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed poignant presentations from the 2021 American Epilepsy Society Annual Meeting. [WATCH TIME: 7 minutes]

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed numerous presentations from AES 2021 that bolstered cenobamate’s known efficacy and safety profile. [WATCH TIME: 7 minutes]

Investigators suggest further studies to better determine is NPC had measurable benefits for patient quality of life.

Across all surgical procedures, the percentage of patients with seizure freedom for at least 12 months ranged from 20% to 35.7% for patients receiving cenobamate.

The scientific director at the Dravet Syndrome Foundation commented on the concern associated with vaccination in this patient population, noting that investigators have not observed an exacerbated risk profile with the COVID-19 vaccines. [WATCH TIME: 2 minutes]

In total, 6.4% of those with intellectual disability achieved seizure freedom and 37.5% had at least a 50% responder rate after treatment with perampanel.

While typically thought of as a disease that affects younger populations, Rebecca O’Dwyer, MD, stressed the importance and nuances of caring for older adults with epilepsy.

The scientific director at the Dravet Syndrome Foundation discussed a recent survey asking caregivers about the experiences of patients with DS following COVID-19 vaccination. [WATCH TIME: 3 minutes]

Findings presented at AES 2021 included data from children with tuberous sclerosis complex and drug refractory epilepsy who were not candidates for epilepsy surgery.

Four out of 6 patients with CDKL5 deficiency disorder and comorbid Lennox-Gastaut syndrome had a decrease in frequency of major motor seizures when treated with ganaxolone.